Highly Selective Targeting of Hepatic Stellate Cells for Liver Fibrosis Treatment Using a D-Enantiomeric Peptide Ligand of Fn14 Identified by Mirror-Image mRNA Display

摘要

Although liver fibrosis is a major public health issue, there is still no effective drug therapy in the clinic. Fibroblast growth factor-inducible 14 (Fn14), a membrane receptor highly specifically expressed in activated hepatic stellate cells (HSCs), is the key driver of liver fibrosis, and thus, it has a great potential as a novel target for the development of effective treatment. Here, we identified a D-enantiomeric peptide ligand of Fn14 through mirror-image mRNA display. This included the chemical synthesis of a D-enantiomer of the target protein (extracellular domain of Fn14), identification of an L-peptide ligand of D-Fn14 using a constructed mRNA peptide library, and identification of a D-enantiomer of the L-peptide, which is a ligand of the natural Fn14 for reasons of symmetry. The obtained D-peptide ligand showed strong binding to Fn14 while maintaining high proteolytic resistance. As-a targeting moiety, this D-peptide successfully mediated high selectivity of activated HSCs for liposomal vehicles compared to that of other major cell types in the liver and significantly enhanced the accumulation of liposomes in the liver fibrosis region of a carbon tetrachloride-induced mouse model. Moreover, in combination with curcumin as an encapsulated load, a liposomal formulation conjugated with this D-peptide showed powerful inhibition of the proliferation of activated HSCs and reduced the liver fibrosis to a significant extent in vivo. This Fn14-targeting strategy may represent a promising approach to targeted drug delivery for liver fibrosis treatment. Meanwhile, the mirror-image mRNA display can provide a new arsenal for the development of D-peptide-based therapeutics against a variety of human diseases.